Eli Lilly starts building $5B antibody-drug conjugate plant in Virginia
Eli Lilly began building a $5 billion plant near Richmond, Virginia, for antibody-drug conjugate medicines, expected to add 650 high-wage jobs.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Eli Lilly has begun construction of a $5 billion fully integrated manufacturing site near Richmond, Virginia. According to TradingView, which cites a company release distributed by PR Newswire, the facility will produce active pharmaceutical ingredients and finished antibody-drug conjugate medicines on one campus.
The company expects the project to create 650 high-wage jobs. The site is described as the first integrated API-to-finish facility in Lilly's network, and it is one of ten U.S. sites the company has built since 2020.
why it matters
For investors, the project signals that drugmakers are still expanding U.S. production. Vertical integration from ingredient to finished drug can reduce bottlenecks and improve supply control, but 650 jobs also add fixed costs. Stronger catalysts would be regulatory approvals or launches that require this capacity, along with details on start-up timing and output volume.
market impact
LLY: large capex for oncology capacity supports long-term supply but raises fixed costs.
tags
instruments
sources
- Eli Lilly and Company (LLY) Breaks Ground On $5B Integrated ADC Plant In Virginia — TradingView, 22 October 2026 at 14:30 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗